Posts

AstraZeneca’s pipeline struggles continue with disappointing late-stage cancer and rare disease data

on

Novartis drops phase 2 radioligand therapy, but CEO’s commitment to the modality unchanged

on

Lilly Was Already Pharma’s Biggest Company. Now It’s Doing Deals to Match

on

Ipsen signals more deals to continue buying spree

on

Osanni Bio raises $190M to advance ophthalmology and cardiology pipeline, including dry AMD candidate

on

AbbVie's $10.9B Move for Apogee's Long-Acting I&I Drug Candidates

on

Treeline to go public via reverse merger with Standard BioTools

on

Merck KGaA Axes SpringWorks Pipeline Assets Amid Pipeline Clear-Out While Pursuing M&A for External Innovation

on

Daiichi Sankyo Targets Nearly $15B in Oncology Sales by 2030 via ADC Franchise Expansion

on

BeOne Streamlines Oncology Pipeline: Shelves CDK2 and KRAS Inhibitors, Advances Degraders

on

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

on

Amgen Abandons Cancer and Sjögren's Candidates Due to Weak Phase 2 Data

on

Bristol Myers Squibb's Pipeline Focus in Pivotal 2026

on

Biogen Pursues Early-Stage Assets to Build Next Generation Growth Pipeline

on

Beeline Biotech Launches with $300M Funding and Bristol Myers Squibb-Derived Pipeline

on

JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus

on

Exclusive: Charles Fuchs departs Roche to become Chief Medical Officer at Tubulis, steering ADC pipeline after $401M Series C

on

Pfizer Reduces Stake in BioNTech; Candel Pauses Pancreatic Cancer Program

on

Takeda Makes Pipeline Cuts and Faces Softer Q2 Sales Due to Generic Competition

on

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

on